血清血管内皮生长因子A作为在转移性非小细胞肺癌中添加贝伐单抗至化疗免疫疗法的生物标志物。
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC.
作者信息
Tanaka Kentaro, Sugisaka Jun, Shiraishi Yoshimasa, Watanabe Yasutaka, Daga Haruko, Azuma Koichi, Nishino Kazumi, Mori Masahide, Ota Takayo, Saito Haruhiro, Hata Akito, Sakaguchi Tadashi, Kozuki Toshiyuki, Akamatsu Hiroaki, Matsumoto Hirotaka, Tachihara Motoko, Wakuda Kazushige, Sato Yuki, Ozaki Tomohiro, Tsuchiya-Kawano Yuko, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Okamoto Isamu
机构信息
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
出版信息
Nat Commun. 2025 Mar 22;16(1):2825. doi: 10.1038/s41467-025-58186-7.
Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previously reported APPLE study, a phase 3 trial evaluating the efficacy of the bevacizumab in combination with atezolizumab, plus platinum chemotherapy in metastatic, nonsquamous non-small cell lung cancer (NSCLC). We investigated the correlation of serum VEGF-A and its isoforms at baseline with treatment response by using an enzyme-linked immunosorbent assay. We reveal that the addition of bevacizumab significantly improves the progression-free survival in patients with the low VEGF-A level. Our results demonstrate that measuring serum VEGF-A or its isoforms may identify NSCLC patients who are likely to benefit from the addition of bevacizumab to immunotherapy. These assays are easy to measure and have significant potential for further clinical development.
抗血管内皮生长因子（VEGF）药物与免疫疗法联合使用已改善了癌症患者的治疗效果，但尚未阐明预测性生物标志物。我们在此报告一项在先前报道的APPLE研究中的预先计划分析，这是一项3期试验，评估贝伐单抗联合阿替利珠单抗加铂类化疗在转移性非鳞状非小细胞肺癌（NSCLC）中的疗效。我们使用酶联免疫吸附测定法研究了基线时血清VEGF-A及其异构体与治疗反应的相关性。我们发现，添加贝伐单抗可显著改善VEGF-A水平低的患者的无进展生存期。我们的结果表明，检测血清VEGF-A或其异构体可能有助于识别可能从免疫疗法中添加贝伐单抗中获益的NSCLC患者。这些检测方法易于测量，具有进一步临床开发的巨大潜力。
Zotero 插件